Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease

Clinical and Experimental Immunology

Volumn 161, Issue 3, 2010, Pages 518-526

  Wasserman, R L ^a   Irani, A M ^b   Tracy, J ^c   Tsoukas, C ^h   Stark, D ⁱ   Levy, R ^d   Chen, J ^e   Sorrells, S ^e   Roberts, R ^f   Gupta, S ^g  

^a DallasAllergyImmunology   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Allergy Asthma and Immunology Associates   (United States)

^d Family Allergy and Asthma Center   (United States)

^e Talecris Biotherapeutics Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Gamunex ; Intravenous IgG; Pharmacokinetics; Primary immunodeficiency disease; Subcutaneous IgG

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; SINUSITIS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; SINUSITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955738662     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04195.x     Document Type: Article

References (32)

1. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins - a review of the literature. Clin Rev Allergy Immunol 2010 38 : 201 269.
2. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 117 (Suppl. S525 53.
3. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008 28 : 803 819, ix.
4. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, the Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006 26 : 265 273.
5. Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006 26 : 177 185.
6. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000 20 : 94 100.
7. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007 96 : 1474 1478.
8. Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol 2005 1 : 120 130.
9. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006 26 : 65 72.
10. Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006 26 : 400 405.
11. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008 28 : 370 378.
12. Gardulf A, Borte M, Ochs HD, Nicolay U, the Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008 126 : 81 8.
13. Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004 114 : 936 942.
14. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987 1 : 1075 1077.
15. Quartier P, Debré M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999 134 : 589 596.
16. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008 122 : 210 212.
17. Bonilla FA, Bernstein IL, Khan DA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005 94 (5 Suppl. 1 S1 63.
18. Eijkhout HW, van Der Meer JWM, Kallenberg CGM et al. for the Inter-University Working Party for the Study of Immune Deficiencies. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001 135 : 165 174.
19. Gelfand EW, Hanna K, the IGIV-C Increased Maximum Infusion Rate Study Group. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol 2006 26 : 284 290.
20. Roifman CM, Schroeder H, Berger M et al., the IGIV-C in PID Study Group. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003 3 : 1325 1333.
21. Ballow M, Berger M, Bonilla FA et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003 84 : 202 210.
22. Waniewski J, Gardulf A, Hammarström L. Bioavailability of γ-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994 14 : 90 7.
23. Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972 1 : 1208 1212.
24. Vivaglobin [package insert]. Marburg, Germany : CSL Behring GmbH, 2007.
25. US Department of Health and Human Services. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Washington, DC : US Department of Health and Human Services, 2008.
26. Hughes RAC, Donofrio P, Bril V et al. on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 7 : 136 144.
27. Bril V, Katzberg H, Donofrio P et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009 39 : 448 455.
28. Merkies ISJ, Bril V, Dalakas MC et al. on behalf of the ICE Study Group. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 2009 72 : 1337 1344.
29. Aebersold P. Regulatory requirements for subcutaneous Ig for PID. In : US Department of Health and Human Services, eds. Intravenous immune globulins in the 21st century: progress and challenges in efficacy, safety, and paths to licensure. Bethesda, MD : US Department of Health and Human Services, 2005. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/ WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054437.pdf (accessed 16 October 2009).
30. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008 28 : 779 802, vii.
31. Desai S, Poll J, Chouksey A, Berger M. Randomized, crossover study of the efficacy and tolerability of the same dose of Gamunex® given subcutaneously or intravenously. J Allergy Clin Immunol 2008 121 : 85.
32. Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008 152 : 274 279.